Table 3.
Most Frequently Reported Adverse Events in Study 2 (Safety Population*)
| No. (%) of Subjects | ||
|---|---|---|
| Event | Placebo (n = 4) |
MEDI-528 50 mg (n = 7) |
| Blood glucose increased | 0 (0.0) | 2 (28.6) |
| Back pain | 1 (25.0) | 1 (14.3) |
| Injection site irritation | 1 (25.0) | 1 (14.3) |
| Blood bicarbonate increased | 0 (0.0) | 1 (14.3) |
| Cyst | 0 (0.0) | 1 (14.3) |
| Lipase increased | 0 (0.0) | 1 (14.3) |
| Lower respiratory tract infection | 0 (0.0) | 1 (14.3) |
| Nuclear MRI abnormal | 0 (0.0) | 1 (14.3) |
Values are shown in descending order of frequency in the MEDI-528 group. MRI = magnetic resonance imaging.
*Consisted of all subjects who received the study drug.